SCHEMBL6932152

SCHEMBL6932152

CSc1nc(-c2ccncc2)c(-c2cccc(C)c2)c(=O)n1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.53
MAPK9 P45984 3/20 0.53
MAP4K4 O95819 2/20 0.53
CDC42BPA Q5VT25 2/20 0.53
MINK1 Q8N4C8 2/20 0.53
FRK P42685 1/20 0.53
CSNK1A1 P48729 1/20 0.53
MAP4K5 Q9Y4K4 1/20 0.53
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
MAPK14 Q16539 9/20 0.45
MAPK13 O15264 3/20 0.45
MAPK12 P53778 2/20 0.45
MAPK11 Q15759 2/20 0.45
TDP2 O95551 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TGFBR1 P36897 1/20 0.39
CSNK1E P49674 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5847695 0.87 ALDH1A1 (0.46) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL5790262 0.84 MAPK14 (0.45) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL4816410 0.83 MAPK14 (0.54) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL5787744 0.83 CSNK1D (0.55) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL5792669 0.79 MAPK14 (0.68) ALDH1A1KDM4ELMNAMAPK14MAPK13
SCHEMBL27224359 0.79 ALDH1A1 (0.60) ALDH1A1KDM4ELMNAMAPK14MAPK13
SCHEMBL6933235 0.74 MAPK14 (0.53) ALDH1A1KDM4ELMNAMAPK14MAPK13
SCHEMBL5786968 0.72 CDC7 (0.47) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL5786878 0.71 MAPK14 (0.50) CSNK1DMAPK9MAP4K4CDC42BPAMINK1
SCHEMBL5786467 0.71 MAPK14 (0.44) ALDH1A1KDM4ELMNAMAPK14TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
EP-1037881-B1 PROCESS OF PREPARING SUBSTITUTED PYRIMIDINONES AMGEN INC (US) 2003-11-12 EP disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
EP-1037881-A1 PROCESS OF PREPARING SUBSTITUTED PYRIMIDINONES Amgen Inc. (US) 2000-09-27 EP disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 EP disclosed
WO-1999028303-A1 PROCESS OF PREPARING SUBSTITUTED PYRIMIDINONES AMGEN, INC. (US) 1999-06-10 WO disclosed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A CSNK1D 1761/4885MAPK9 1247/4885MAP4K4 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.